Table 1 The number of adverse event reports of SGLT2 inhibitors.
Type of SGLT2 inhibitors | Drugs | Case (n) | Reporting ratio (%) |
|---|---|---|---|
Total | Â | 6150 | - |
Canagliflozin | Canagliflozin Hydrate | 661 | 10.75 |
| Â | Canagliflozin Hydrate/Teneligliptin Hydrobromide Hydrate | 142 | 2.31 |
Dapagliflozin | Dapagliflozin Propylene Glycolate Hydrate | 1279 | 20.80 |
Empagliflozin | Empagliflozin | 919 | 14.94 |
| Â | Empagliflozin/Linagliptin | 79 | 1.29 |
Ipragliflozin | Ipragliflozin L-Proline | 1984 | 32.26 |
| Â | Ipragliflozin L-Proline/Sitagliptin Phosphate Hydrate | 143 | 2.33 |
| Â | Ipragliflozin L-Proline | 2 | 0.03 |
| Â | Ipragliflozin | 1 | 0.02 |
Luseogliflozin | Luseogliflozin Hydrate | 489 | 7.95 |
Tofogliflozin | Tofogliflozin Hydrate | 451 | 7.33 |
